Navigation Links
Nastech to Host 2007 Analyst and Institutional Investor Day

BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) will be hosting an analyst and institutional investor day in New York City on Thursday, October 4, 2007 from 12:00 p.m. - 3:00 p.m. Eastern Time at the Westin New York at Times Square, on 270 West 43rd Street. The luncheon event will feature a presentation from Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer and Gordon Brandt, M.D., Executive Vice President, Clinical Research and Medical Affairs of Nastech as well as the following leading scientific experts:

-- Robert S. Lindsay, M.B.Ch.B., Ph.D., F.R.C.P., Chief of Internal

Medicine, Helen Hayes Hospital and Director of its Clinical Research

Center, and Professor of Clinical Medicine, Columbia University, will

provide an overview of osteoporosis and give expert insight on the use

of Parathyroid Hormone (PTH1-34) as a therapy for this disease.

-- Zachary T. Bloomgarden, M.D., Clinical Professor,

Medicine/Endocrinology Diabetes and Bone Disease, Department of

Medicine, Mount Sinai Medical Center, will present on diabetes and

discuss current treatment regimens for the disease as well as those

being developed.

-- Carl D. Novina, M.D., Ph.D., Assistant Professor, Cancer Immunology and

AIDS, Dana-Farber Cancer Institute, and Assistant Professor, Department

of Pathology, Harvard Medical School, will present on the emerging

field of RNA interference (RNAi) and its potential application as a


"Nastech continues to make significant progress in its peptide and protein therapeutic programs utilizing our non-injectable drug delivery technology as well as the development of RNAi therapeutics and now has a strong pipeline of products in or preparing to initiate Phase II clinical trials," stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. "For this year's analyst and institutional investor day event, Nastech is pleased to have gathered leading experts in their respective fields to highlight three areas at the core of Nastech's drug development. This event will also lend insight into Nastech's technologies and business, as we continue to execute upon a strategy that we believe has the potential to deliver important therapies to patients while creating significant value for our shareholders."

The invitation-only event will be webcast commencing at 12:30 p.m. Eastern Time. To access the live webcast for this conference, please log on to Nastech's website at approximately 15 minutes prior to the presentation in order to register and download any necessary software.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at

Nastech Forward-Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech assumes no obligation to update and supplement forward-looking statements because of subsequent events.



Ed Bell

Director, Investor Relations

(425) 908-3639

Russo Partners, LLC

Matthew Haines (Investors/Media)

(212) 845-4235

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. measurement of green fluorescent proteins and a red fluorescent protein in live cells in the Analyst GT multimode reader
2. Venture Investors early-stage fund grows to $115 million
3. Investor warns of angel-venture funding gap
4. Brazilian bio-industry should impress American investors
5. Investors raise $25 million for biodiesel plant
6. Bio-energy and cleantech grab attention of investors
7. Venture Investors to open Michigan office
8. Early-stage executives hear from investors
9. Commerce qualifies seven for investor tax credits
10. Investor links East Coast funds to Midwest tech
11. Angel investors commit $12.7B in first half of `06
Post Your Comments:
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... PHILADELPIA, PA (PRWEB) , ... November 24, 2015 , ... ... young entrepreneurs at competitive events in five states to develop and pitch their BIG ... student projects from each state are competing for votes to win the title of ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 th ... from 17 th until 19 th November 2015.   ... the first combined scanner in the world which scans both ... two different scanners were required: one for passports and one ... same surface. This innovation is an ideal solution for electronic ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):